Skip to main content
MANE
NYSE Life Sciences

Veradermics' Hair Loss Drug VDPHL01 Achieves Highly Positive Phase 2/3 Results, Paving Way for Potential Market Disruption

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$82.5
Mkt Cap
$2.533B
52W Low
$32
52W High
$80.9
52W Position info
158% above low
Off High info
at 52W high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Veradermics announced positive topline data from its Phase 2/3 clinical trial for VDPHL01, an oral treatment for male pattern hair loss, meeting all primary and key secondary endpoints with strong efficacy and a favorable safety profile.


Key Events · Product Development and Regulatory · MANE

  • VDPHL01 Phase 2/3 Trial Success

    The VDPHL01 (oral minoxidil) Study '302' met all primary and key secondary endpoints with high statistical significance in males with mild-to-moderate pattern hair loss.

  • Strong Efficacy and Safety Profile

    The trial demonstrated robust hair growth (30.3-33.0 hairs/cm² increase vs. 7.3 for placebo) and patient-reported improvements, alongside a favorable safety profile with no treatment-related serious adverse events.

  • Potential First-in-Class Oral Treatment

    Veradermics believes VDPHL01 could be the first FDA-approved non-hormonal oral treatment for pattern hair loss in nearly 30 years, targeting an estimated 80 million people in the U.S.

  • Upcoming Clinical Milestones

    The company anticipates male confirmatory Phase 3 data (Study '304') and Study '302' Part B data in the second half of 2026, with active recruitment for a female pattern hair loss trial (Study '306').


Analysis · MANE · Life Sciences

This 8-K announces highly positive topline data from the Phase 2/3 clinical trial for VDPHL01, a potential groundbreaking oral treatment for pattern hair loss. The trial successfully met all primary and key secondary endpoints with strong statistical significance, demonstrating robust hair growth and a favorable safety profile. This represents a significant de-risking event for Veradermics' lead product candidate, which aims to be the first FDA-approved non-hormonal oral treatment for this condition in nearly three decades, addressing a massive market. The positive clinical outcome, coupled with recent substantial insider buying, suggests strong internal confidence in the company's prospects. With the stock already trading above its 52-week high, this news could fuel further upward momentum as the company progresses towards confirmatory Phase 3 trials and potential regulatory approval.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 51.3% of the 191 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $82.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $32.00 to $80.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $141.66 info
Change: -$0.345 (-0.24%) info
Market Cap: $5.918B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $141.66 info
Change: +$2.32 (+2%) info
Market Cap: $5.918B info
MANE
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $108.01
Real-time Price: $141.66 info
Change: +$33.64 (+31%) info
Market Cap: $5.918B info
MANE
Oct 18, 2026, 6:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $108.82
Real-time Price: $141.66 info
Change: +$32.84 (+30%) info
Market Cap: $5.918B info
MANE
Aug 21, 2026, 6:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $102.82
Real-time Price: $141.66 info
Change: +$38.84 (+38%) info
Market Cap: $5.918B info